Madrigal Pharmaceuticals, Inc.
MDGL
$532.58
-$14.08-2.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.32% | 20.98% | 38.12% | 44.26% | 44.77% |
| Total Depreciation and Amortization | 271.01% | 272.34% | 330.29% | 258.74% | 114.61% |
| Total Amortization of Deferred Charges | -3.34% | -13.53% | -23.22% | -31.44% | -30.74% |
| Total Other Non-Cash Items | 60.34% | 38.56% | 26.96% | 22.02% | 14.46% |
| Change in Net Operating Assets | 89.36% | 12.06% | 88.25% | 287.85% | -716.72% |
| Cash from Operations | 35.68% | 32.18% | 58.39% | 62.74% | 31.53% |
| Capital Expenditure | -779.77% | -290.59% | 68.06% | 54.32% | 47.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 247.59% | 131.31% | 112.01% | 92.81% | 88.74% |
| Cash from Investing | 221.67% | 129.07% | 111.78% | 92.66% | 88.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -11.96% | -81.33% | -94.82% | -95.99% | -96.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 567.42% | 46.87% | -65.18% | -77.68% | -96.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 132.97% | 110.04% | 1,835.03% | -64.12% | -173.01% |